Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ABCD = adiposity-based chronic disease; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACE = American College of Endocrinology; ACEI = angiotensin-converting enzyme inhibitor; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CGM = continuous glucose monitoring; CHD = coronary heart disease; CKD = chronic kidney disease; DKA = diabetic ketoacidosis; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density-lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low-density-lipoprotein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiologic evidence shows a continuous relationship between A1C and CVD and all-cause mortality.72”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [72]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cited by
Items 101–200 of 610
Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
Mohan, V., Saboo, B., Khader, J., Modi, K. D., Jindal, S., WANGNOO, S. K., & Sugumaran, A. (2022) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514221074663 · Cited by 35
Wong, S. Y., Lee, A. R. Y. B., Sia, A. H. J., Wo, Y. J., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Ong, C. C., Teo, L., Yeo, T., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07360-w · Cited by 30
“Prominent guidelines including the European Society of Cardiology Guidelines on Diabetes in 2019 [65], American College of Cardiology/American Heart Association Primary Prevention of Cardiovascular Guidelines in 2019 [66], American Association of Clinical Endocrinologists Consensus Statement in 2020 [67] and Research…”
El-Sawaf, E. S., Saleh, S., Abdallah, D. M., Ahmed, K. A., & El-Abhar, H. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119697 · Cited by 26
RetractedGómez‐Huelgas, R., Sanz‐Cánovas, J., Cobos-Palacios, L., Sampalo, A. L., & Perez-Belmonte, L. M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.11.008 · Cited by 27
Mitchell, S. E., Bragg, A., Cruz, B. A. D. L., Winter, M. R., Reichert, M., Laird, L. D., Moldovan, I., Parker, K., Martin-Howard, J., & Gardiner, P. M. (2023) · Journal of Medical Internet Research · doi:10.2196/43669 · Cited by 35
“Recommendations for medication adjustments were based on an algorithm [26] and shared with primary care providers via progress notes in the electronic health record.”
MethodOptimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach
Isaacs, D. M., Kruger, D. F., & Spollett, G. R. (2020) · Diabetes Spectrum · doi:10.2337/ds20-0016 · Cited by 26
“addition of other antihyperglycemic medications should be considered (8,9).”
BackgroundIntegrating oral semaglutide into clinical practice in primary care: for whom, when, and how?
Brunton, S., Mosenzon, O., & Wright, E. E. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798162 · Cited by 29
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
“somewhat different inclusion criteria but with similar targets for LDL-C, non-HDL-C, and apoB as the three risk categories for T2DM patients of the ESC/EAS 2019 guidelines [48].”
BackgroundLee, J., Kim, H.-J., Park, C. S., Park, S. Y., Park, S., Lee, H. J., Kim, S., & Cho, Y. S. (2022) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2022.14.4.412 · Cited by 25
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 26
“American Association of Clinical Endocrinologists/ American College of Endocrinology – Comprehensive Type 2 Diabetes Management Algorithm (2020) [34] For patients with TG levels 1.”
BackgroundSelf-citationKalyani, R. R., Allende-Vigo, M. Z., Antinori-Lent, K. J., Close, K. L., Das, S. R., Deroze, P., Edelman, S. V., El Sayed, N. A., Kerr, D., Neumiller, J. J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad745 · Cited by 25
Blaine, E., Tumlinson, R., Colvin, M., HAYNES, T. G., & Whitley, H. P. (2022) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2659 · Cited by 26
Yabe, D., Deenadayalan, S., Horio, H., Kaneto, H., Jensen, T. B., Terauchi, Y., Yamada, Y., & Inagaki, N. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13764 · Cited by 23
Cheng, H., Jia, Z., Li, Y., Yu, X., Wang, J. J., Xie, Y. J., Hernández, J., & Wang, H. (2024) · JMIR Public Health and Surveillance · doi:10.2196/49617 · Cited by 28
“Recommendations stress that the initiation of intervention during the stage of IR, instead of after a T2DM diagnosis, is more effective in reducing treatment burden and overall health care costs [13].”
BackgroundDavies, M. J., Bianchi, C., & Del Prato, S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154242 · Cited by 23
Ji, L., Chan, J. C. N., Yu, M., Yoon, K., Kim, S. G., Choi, S. H., Huang, C., Tu, S., Wang, C., Paldánius, P. M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14205 · Cited by 28
Ertugliflozin in the treatment of type 2 diabetes mellitus
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-4 · Cited by 31
Cugno, C., Kizhakayil, D., Calzone, R., Rahman, S. M., Halade, G. V., & Rahman, M. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-89827-8 · Cited by 24
Kalra, S., Mithal, A., Zargar, A. H., Sethi, B. K., Dharmalingam, M., Ghosh, S. K., & Sen, R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.1.63 · Cited by 27
Emad-Eldin, M., Balata, G. F., el-Shorbagy, E., Hamed, M. S., & Attia, M. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.828 · Cited by 31
González‐González, J. G., Solís, R. C., González-Colmenero, A. D., Raygoza-Cortez, K., Moreno-Peña, P. J., Sánchez, A. L., McCoy, R. G., Ospina, N. S., Maraka, S., Brito, J. P., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109821 · Cited by 24
Cardiometabolic-based chronic disease: adiposity and dysglycemia drivers of heart failure
Correia, E. T. D. O., Mechanick, J. I., Barbetta, L. M. D. S., Jorge, A. J. L., & Mesquita, E. T. (2022) · Heart Failure Reviews · doi:10.1007/s10741-022-10233-x · Cited by 24
“In patients with IR, current strategies focus on weight loss and healthy lifestyle to reduce ectopic fat (improve insulin sensitivity) and avoid progression to prediabetes and T2D [94].”
BackgroundInfluentialSelf-citationMentored implementation to initiate a diabetes program in an underserved community: a pilot study
Vaughan, E. M., Naik, A. D., Amspoker, A. B., Johnston, C. A., Landrum, J., Balasubramanyam, A., Virani, S. S., Ballantyne, C. M., & Foreyt, J. P. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002320 · Cited by 24
Kushner, P. R., Cavender, M. A., & Mende, C. W. (2022) · Clinical Diabetes · doi:10.2337/cd21-0119 · Cited by 29
“In line with recommendations from both the American Academy of Clinical Endocrinology and the ADA, this patient would have been an ideal candidate for outpatient therapy with an SGLT2 inhibitor (59,76).”
ResultMohan, V., Joshi, S., Mithal, A., Kesavadev, J., Unnikrishnan, A., Saboo, B., Kumar, P. R. G., Chawla, M. S., Bhograj, A., & KOVIL, R. R. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01355-4 · Cited by 31
“In February 2019, the Advanced Technologies and Treatments for Diabetes (ATTD) Congress formalized guidelines for CGM and TIR goals, which have been endorsed by the ADA and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) [7, 25, 42].”
BackgroundFanshier, A. V., Crews, B. K., Garrett, M. C., & Johnson, J. L. (2023) · Clinical Diabetes · doi:10.2337/cd22-0060 · Cited by 22
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
Wong, C. K. H., Lau, K. T. K., Tang, E. H. M., Lee, C., Lee, C. Y. Y., Woo, Y. C., Au, I. C. H., Tan, K. C. B., & Lui, D. T. W. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01520-w · Cited by 21
Association of hemoglobin A1c time in range with risk for diabetes complications
Mohr, D. C., Zhang, L., Prentice, J. C., Nelson, R. E., Li, D., Pleasants, E. A., & Conlin, P. R. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002738 · Cited by 29
Bradley, M. D., Arnold, M. E., Biskup, B., Campbell, T. M., Fuhrman, J., Guthrie, G. E., Kelly, J. H., Lacagnina, S., Loomis, J. F., McMacken, M. M., et al. (2022) · Clinical Diabetes · doi:10.2337/cd22-0009 · Cited by 23
“Both the American Diabetes Association (ADA) (30,31) and the American Association of Clinical Endocrinology (32) recommend lifestyle optimization as part of medical care for type 2 diabetes.”
BackgroundAssociation of gene polymorphisms with body weight changes in prediabetic patients
Valeeva, F. V., Medvedeva, M. S., Khasanova, K. B., Валерьевна, В. Е., Киселева, Т. А., Egorova, E. S., Pickering, C., & Ahmetov, I. I. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07254-y · Cited by 22
“Thus, alongside advocating glycemic control, recommendations from various endocrinological associations highlight the importance of a reduction in patient body weight by 5–10% from the initial presentation [11, 12].”
BackgroundPouryousefi, E., Javadi, M., Hashemipour, S., Nooshabadi, M. R., & Haghighian, H. K. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00848-3 · Cited by 19
“Although according to recent studies, metformin is mainly used to control and treat pre-diabetes along with healthy diet and increased physical activity, but the results of clinical studies show that lifestyle interventions causes better control of these conditions and also effective in reducing the conversion of pred…”
BackgroundChadha, M. D., Jain, S. M., Chawla, R., Dharmalingam, M., Chaudhury, T., Talwalkar, P., Tripathi, S., Singh, S., Gutch, M., & Dasgupta, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230116150205 · Cited by 20
Hyun, M. K., Lee, J. W., & Ko, S. (2023) · BMC Public Health · doi:10.1186/s12889-023-15763-z · Cited by 26
Koshy, A. N., Murphy, A. C., Farouque, O., Ramchand, J., Burrell, L. M., & Yudi, M. (2020) · Internal Medicine Journal · doi:10.1111/imj.15002 · Cited by 21
Examining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
“lipidaemia, hypertension, CKD, CVD, non-alcoholic fatty liver disease (NAFLD), osteoporosis, depression, sleep apnoea, and certain types of cancers.(7,14) Improved glycaemic control alone will not adequately”
BackgroundSelf-citationAbdollahi, M., Marandi, S. M., Ghaedi, K., Safaeinejad, Z., Kazeminasab, F., Shirkhani, S., Sanei, M. H., Rezvanian, P., & Nasr‐Esfahani, M. H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5318245 · Cited by 21
“Prediabetics have 3-10 times the risk of progressing to type 2 diabetes mellitus (T2DM) compared to nonprediabetics [5].”
BackgroundCheng, W., Chen, H., Tian, L., Ma, Z., & Cui, X. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1157270 · Cited by 21
“Cardiologists tend to analyze 24-h HRV, whereas internists tend to detect whether HRV is abnormal in different physiological states, known as Ewing test (Gerritsen et al., 2001).”
BackgroundEgede, L. E., Bogdanov, A., Fischer, L., Fernandes, J. D. D. R., & Kallenbach, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00850-w · Cited by 18
Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies
Koufakis, T., Grammatiki, M., & Kotsa, K. (2020) · Maturitas · doi:10.1016/j.maturitas.2020.10.005 · Cited by 19
Li, Y., Wang, Y., Hu, X., Chen, J., Li, Y., Zhong, Q., Cheng, H., Mohammed, B. H., Liang, X., Hernández, J., et al. (2021) · Healthcare · doi:10.3390/healthcare9050580 · Cited by 20
Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
Gómez‐Pérez, A. M., Damas-Fuentes, M., Cornejo-Pareja, I. M., & Tinahones, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194497 · Cited by 20
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D. S., & Izzy, M. J. (2021) · Hepatology Communications · doi:10.1002/hep4.1876 · Cited by 19
Controversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis
Quispe, R., Alfaddagh, A., Kazzi, B., Zghyer, F., Marvel, F. A., Blumenthal, R. S., Sharma, G., & Martin, S. S. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01031-9 · Cited by 17
Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus
Clements, J. N., Isaacs, D. M., Hartman, R. E., & Gambill, K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00951-6 · Cited by 22
Boye, K. S., Lage, M. J., & Thieu, V. T. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01212-4 · Cited by 19
Hu, G., Gu, H., Jiang, Y., Yang, X., Wang, C., Jiang, Y., Li, Z., Wang, Y., & Wang, Y. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11112-z · Cited by 17
Kalra, S., Das, S., & Zargar, A. H. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_522_21 · Cited by 24
“When patients fail to achieve glycaemic control while on metformin with or without other oral antihyperglycaemic agents, current treatment guidelines recommend considering a variety of options including GLP‐1RAs, sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors, DPP‐4 inhibitors, sulphonylureas and thiazolidinedione…”
BackgroundKim, S. Y., Park, S., Kim, B., Min, C., Cho, W., Yon, D. K., Kim, J. Y., Han, K.-D., Rhee, E., Lee, W., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110626 · Cited by 17
Cheong, M., Chew, S. T. H., Oliver, J. S., Baggs, G. E., Low, Y. L., How, C. H., Tan, N. C., Huynh, D. T. T., & Tey, S. L. (2020) · Nutrients · doi:10.3390/nu12113329 · Cited by 24
“However, the true prevalence of vitamin B12 deficiency among the older adults in Singapore is likely to be higher, as our study cohort excluded individuals with type 2 diabetes, and there is a known association between the use of metformin and vitamin B12 deficiency in people with diabetes [98,99].”
BackgroundNaing, S., Ramesh, G., Garcha, J., Poliyedath, A., Khandelwal, S., & Mills, P. K. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.204 · Cited by 17
New Antidiabetes Medications and Their Cardiovascular and Renal Benefits
Ferro, E. G., Elshazly, M. B., & Bhatt, D. L. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.007 · Cited by 19
Efficacy and Safety of Meal Replacement in Patients With Type 2 Diabetes
Ye, W., Xu, L., Ye, Y., Zeng, F., Lu, X., Li, Y., & Liu, L. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad273 · Cited by 17
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Asrani, S. K., Hall, L., Reddy, V., Ogola, G., & Izzy, M. J. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001909 · Cited by 16
“, glucagon-like peptide 1 receptor agonists and sodiumglucose cotransporter-2 inhibitors) in highly prevalent populationswith obesity anddiabetesmellitus suchas ours (35).”
BackgroundNeumiller, J. J., Lienhard, F. J., Alicic, R. Z., & Tuttle, K. R. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.106 · Cited by 18
Visolyi, G. Á., Domján, B. A., Svébis, M. M., Péterfi, A., Lovasz, B. D., Mészáros, S., Horváth, V. J., & Tabák, Á. G. (2023) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2023.03.002 · Cited by 18
“patients.[1, 2] Insulin remains the ultimate glucose-lowering therapy and it is recommended when”
BackgroundFormichi, C., Baronti, W., Gennaro, G., Ceroni, M. C., Nigi, L., Rizzo, L., & Dotta, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02369-4 · Cited by 17
“The switch from sulphonylurea is most likely due to the need to replace drugs associated to a greater risk of hypoglycemia and weight gain [5] with a more effective and safer alternative, which allows oral administration to be maintained [28, 32].”
Banitalebi, E., Ghahfarrokhi, M. M., Faramarzi, M., & Earnest, C. P. (2021) · The Journal of Sports Medicine and Physical Fitness · doi:10.23736/s0022-4707.20.11105-8 · Cited by 18
Changes in Type 2 Diabetes Medication Utilization and Costs in the United States, 2014–2019
Neilson, L. M., Munshi, K. D., Peasah, S. K., Huang, Y., Swart, E. C. S., Henderson, R. R., Manolis, C. H., & Good, C. B. (2021) · Medical Care · doi:10.1097/mlr.0000000000001597 · Cited by 17
Fernando, K., Bain, S. C., Holmes, P., Jones, P. N., & Patel, D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01116-9 · Cited by 18
“In patients with gastroparesis or severe gastro-oesophageal reflux disease, GLP-1 RAs should be used with close monitoring and dose adjustments as needed [83].”
BackgroundLau, K. T. K., Wong, C. K. H., Au, I. C. H., Lau, W. C. Y., Man, K. K. C., Chui, C. S. L., & Wong, I. C. K. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023489 · Cited by 16
Is There a Role for Diabetes-Specific Nutrition Formulas as Meal Replacements in Type 2 Diabetes?
Noronha, J. C., & Mechanick, J. I. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.874968 · Cited by 16
“In addition, clinical practice guidelines by the American Association of Clinical Endocrinology (formerly known as American Association of Clinical Endocrinologists), American Diabetes Association (ADA), Diabetes Canada (formerly known as Canadian Diabetes Association), and the European Association for the Study of Di…”
BackgroundSelf-citationBedros, J. R., Jermendy, G., Gaál, Z., Gerő, L., Hídvégi, T., Kempler, P., Lengyel, C., Várkonyi, T. T., Winkler, G., & Wittmann, I. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.20 · Cited by 21
Choi, I. J., Choo, E. H., Kim, H. J., Lim, S., Moon, D., Lee, K. Y., Hwang, B., Kim, C. J., Park, M., Lee, J. M., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01428-x · Cited by 18
Chishiki, T., Nagatomo, Y., Saji, M., Takei, M., Goda, A., Kohno, T., Nakano, S., Nishihata, Y., Ikegami, Y., Shiraishi, Y., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.07.041 · Cited by 15
Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes
Andraos, J., Smith, S. R., Tran, A., & Pham, D. Q. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01406-6 · Cited by 20
“The AACE guideline of 2023 has included therapy options of either a GLP-1 RA or pio - glitazone for patients who have experienced strokes or tran - sient ischemic attacks, and continues to recommend mono, dual, or triple therapy based on HbA1c laboratory values [ 4, 9].”
MethodChen, K., Wang, Y., Li, D., Li, J., Huang, Y. L., Huang, M., & Ma, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1389538 · Cited by 20
Olufade, T. O., Jiang, L., Israni, R., Huang, J., & Gosmanov, A. R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14530 · Cited by 17
“Another limitation, which concerns the claims data used for this study, is that it did not capture information on patient characteristics that could affect CVD/CKD risk, such as glycaemic variables, body mass index, renal function, smoking status, or family history of CVD/CKD.”
BackgroundInfluentialCasale, M., Baldini, M., Monte, P. D., Gigante, A., Grandone, A., Origa, R., Poggi, M., Gadda, F., Lai, R., Marchetti, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071826 · Cited by 21
Jung, H. N., Cho, Y. K., Min, S. H., Kim, H. S., Kim, Y., Park, J., Lee, W. J., & Jung, C. H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870722 · Cited by 17
Oral GLP1 Analog: Where Does the Tide Go?
Gardner, H. M., & Hamdy, O. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420984130 · Cited by 15
He, Y., Mi, N., Cheng, Z., Xue, H., Han, J., Wang, H., Wang, H. H., Wu, J., Shi, X., Zhao, S., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00196-2 · Cited by 15
Gunsalus, K. T. W., Mixon, J. K., & House, E. M. (2024) · Medical Science Educator · doi:10.1007/s40670-024-02025-9 · Cited by 15
Liao, K. P., Rist, P. M., Giles, J. T., Santacroce, L. M., Connelly, M. A., Glynn, R. J., Ridker, P. M., Tawakol, A. A., Bathon, J. M., & Solomon, D. H. (2024) · Arthritis Research & Therapy · doi:10.1186/s13075-024-03352-3 · Cited by 16
“Lipid subfractions such as LDL particle number (LDL-P) and size are sometimes considered in treatment decisions for some at-risk CVD patients in the general population, but these measurements have not been reported in a cohort with RA [18, 19].”
BackgroundMethodInfluentialPractical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital
Papanastasiou, L., Glycofridi, S., Gravvanis, C., Skarakis, N., Papadimitriou, I., Kanti, G., Kapsali, C., & Kounadi, T. (2020) · HORMONES · doi:10.1007/s42000-020-00256-0 · Cited by 15
“In addition, two of our cases were reclassified as T1D based on autoantibody investigation after the DKA episode.”
BackgroundInfluentialMissel, A. L., Saslow, L. R., Hafez, D., Marvicsin, D. J., Sen, A., Richardson, C. R., & Liu, X. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00645-4 · Cited by 17
Abu-Nejim, H., & Becker, R. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01350-7 · Cited by 16
Elya, B., Forestrania, R. C., Hashim, N. M., & Triadisti, N. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.161007 · Cited by 21
“DPP-4 inhibitors do not cause weight gain, hypoglycemia, or indigestion and can be administered to patients in managing diabetes [11].”
Chianelli, M., Armellini, M., Carpentieri, M. S., Coccaro, C., Cuttica, C. M., Fusco, A., Marucci, S., Nelva, A., Nizzoli, M., Ponziani, M. C., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303282327240507184902 · Cited by 17
Bae, J., Huh, J. H., Lee, M., Lee, Y., & Lee, B. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14259 · Cited by 13
Continuity of Medication Use by US Adults With Diabetes, 2005-2019
Chehal, P. K., Uppal, T. S., Turbow, S. D., Fernandes, G. F., HAW, J. S., Shah, M. K., Rajpathak, S. N., Narayan, K. M. V., & Ali, M. K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53562 · Cited by 13
Using adult stem cells to monitor endothelial dysfunction in diabetes mellitus
Jain, R., Awal, H. B., & Sen, S. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107588 · Cited by 15
Lavernia, F., & Blonde, L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798638 · Cited by 13
Self-citationHemoglobin A1c Threshold for Reduction in Bone Turnover in Men With Type 2 Diabetes Mellitus
Joad, S. S., Ballato, E., Deepika, F., Gregori, G., Fleires-Gutierrez, A. L., Colleluori, G., Aguirre, L. E., Chen, R., Russo, V., Lopez, V. F., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.788107 · Cited by 15
“(group I: 6, group II: 6.0– 6.4, group III: 6.5–6.9, and group IV: ≥7) modified according to clinical guidelines for good control which is 7 as per American Diabetes Association (14) and 6.5 as per American Association of Clinical Endocrinology (15).”
BackgroundInfluentialType 2 diabetes and cardiovascular disease: risk reduction and early intervention
Hinnen, D., Kruger, D. F., & MAGWIRE, M. L. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2126235 · Cited by 21
“Insulin and sulfonylureas can increase the risk of hypoglycemia and weight gain while thiazolidinediones are associated with an increased risk of weight gain [5].”
BackgroundTirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12
Hypoglycemia in type 2 diabetes: It is common, so what strategies can minimize the risk?
LeBras, M. H., & Laubscher, T. A. (2021) · Canadian Family Physician · doi:10.46747/cfp.670135 · Cited by 12
Yang, C., Lin, W., Li, L., Ou, H., & Kuo, S. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2262 · Cited by 14
“In this population, DPP4is are generally preferable because of their relatively low risk of hypoglycemia and neutral cardiovascular effects.(5,6) SUs are low- cost alternatives but require the close blood glucose monitoring due to an increased risk of hypoglycemia.”
BackgroundWu, H., Wei, J., Wang, S., Chen, W., Chen, L., Zhang, J., Wang, N., & Tan, X. Y. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103066 · Cited by 12
Davis, G. M., Peters, A. L., Bode, B. W., Carlson, A. L., Dumais, B., Vienneau, T. E., Huyett, L. M., & Ly, T. T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15993 · Cited by 14
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 16
Zheng, Z., Ding, Y., Qu, Y., Cao, F., & Li, F. (2021) · American Journal of Translational Research · Cited by 28
Lam, P. Y., Chow, S. C., Lam, W., Chow, L. L. W., & Fung, N. S. K. (2021) · Clinical ophthalmology · doi:10.2147/opth.s301317 · Cited by 15
“5%, given if it can be achieved in a safe and affordable manner.(43) It was believed that HbA1c level of ≤6.”
BackgroundCampos, C., & Unger, J. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1971461 · Cited by 13
Hunt, L. M., Arndt, E., Bell, H. S., & Howard, H. (2021) · Journal of Bioethical Inquiry · doi:10.1007/s11673-021-10119-x · Cited by 13
Powell, M. A., Clark, C. N., Alyakin, A., Vogelstein, J. T., & Hart, B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.41505 · Cited by 14
Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States
Nargesi, A. A., Clark, C. N., Aminorroaya, A., Chen, L., Liu, M., Reddy, A., Amodeo, S., Oikonomou, E. K., Suchard, M. A., McGuire, D. K., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.03.002 · Cited by 12
Villalobos, N., Vela, F. S., & Hernández, L. M. (2020) · Journal of Scientific Innovation in Medicine · doi:10.29024/jsim.78 · Cited by 16
Metadata
- Authors
- Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., Garvey, W. T., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Perreault, L., Rosenblit, P. D., Samson, S., & Umpierrez, G. E.
- Affiliations
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California San Diego (US)
- Beth Israel Deaconess Medical Center (US)
- Kaiser Permanente (US)
- Ochsner Health System (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- University of Miami (US)
- Washington University in St. Louis (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Colorado Anschutz (US)
- University of California, Irvine (US)
- Emory University (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 26
- Issue
- 1
- Pages
- 107-139
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3004838676
- Cited by
- 598
- References
- 300
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 80 · 2023: 104 · 2022: 146 · 2021: 125 · 2020: 81
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes management, glycemic control, cardiovascular risk, atherosclerotic cardiovascular disease, chronic kidney disease, diabetic ketoacidosis, obstructive sleep apnea, dyslipidemia, obesity, GLP-1 receptor agonists, SGLT2 inhibitors, insulin therapy, continuous glucose monitoring, self-monitoring of blood glucose
- MeSH terms
- Proprotein Convertase 9, Endocrinologists, Algorithms, Blood Glucose, Diabetes Mellitus, Type 2, Humans, United States, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.